UK volunteers test new ebola vaccine combo in Early-Stage trial
NCT ID NCT02451891
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and immune response of two experimental Ebola vaccines in 38 healthy UK adults. Some volunteers received one vaccine, while others got a prime-boost combination. The vaccines use harmless viruses to train the immune system against Ebola without causing the disease. The study was terminated early, but results help inform future Ebola vaccine development.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital
Oxford, Oxfordshire, OX3 7LE, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ebola vaccine trial aims to shield frontline workers in congo
- Ebola vaccine in a nasal spray? early trial halted
- Ebola vaccine memory under the microscope: how long does it last?
- Could a vaccine and antibody combo stop ebola after exposure?
- Ebola antibody cocktail made available in emergency outbreak
- Hope in a pill? ebola drug favipiravir tested in guinea